Ixazomib pharmacokinetic data from 755 adult patients enrolled across ten studies were adequately described by a three-compartment model with linear distribution and elimination kinetics, including first-order linear absorption with a lag time describing the oral dose pharmacokinetic profile.

The geometric mean terminal disposition phase half-life was 9.5 days, steady-state volume of distribution was 543 L and systemic clearance was 1.86 L/h. The absolute bioavailability of an oral dose was estimated to be 58%.

No ixazomib dose adjustment is required based on body surface area (1.2–2.7 m2), sex, age (23–91 years), race, mild or moderate renal impairment, mild hepatic impairment, and smoking status.